drugset / Trial / NCT03577392
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
Phase 2/3
Unknown
120 enrolled
Sichuan Provincial People's Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To study safety and efficacy of intravenous pump of recombinant human endostatin combined with XELOX-treated and also investigate the potential value of CECs level for the prediction of PD and outcomes in patients with advanced colorectal cancer.
Timeline
- Start
- 2018-07-01
- Primary completion
- 2019-08-01
- Completion
- 2021-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | — | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
Indications
No indication recorded.